QHSLab (USAQ) AI Stock Analysis

Top Page

QHSLab

(Other OTC:USAQ)

Select Model

Rating:66Neutral

Price Target:$0.32▲(8.00% Upside)

Action:reiterated

Date:09/16/26

The score is driven primarily by improving profitability and a de-risked balance sheet, tempered by negative TTM operating/free cash flow that undermines earnings quality. Technicals are moderately supportive with price above key short-term averages and positive MACD, while valuation looks favorable on a low P/E. Recent corporate updates reinforce the operational improvement narrative.

Positive Factors

Revenue and Profitability TurnaroundRevenue has expanded from about $1.41 million in 2023 to $3.02 million on a TTM basis, while profitability has turned positive. The combination of strong gross margin and a 17% net margin indicates improving operating economics and provides a foundation for continued reinvestment.

Negative Factors

Negative Cash ConversionNegative operating and free cash flow show that reported earnings are not currently converting into cash, weakening earnings quality and financial flexibility. If this persists, QHSLab may have less internally generated funding for product development, sales investment, and ongoing obligations.

QHSLab (USAQ) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $4.51M
Dividend Yield: ―
Average Volume (3M): 5,325
Price to Earnings (P/E): 6.3
Beta (1Y): 1.29
Revenue Growth: 24.61%
EPS Growth: ―
Country: US
Employees: 12
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

QHSLab Business Overview & Revenue Model

Company Description

QHSLab, Inc. is a company operating in the medical technology and Software-as-a-Service (SaaS) sectors. Its core focus is on advancing value-based healthcare, medical informatics, and personalized medicine driven by algorithms. The firm also develops...

QHSLab Financial Statement Overview

Summary

Turnaround is evident with higher revenue (TTM ~$3.02M), strong gross margin (~67%), and positive TTM net income (~$0.52M, ~17% margin) alongside a repaired, low-leverage balance sheet (debt-to-equity ~0.06). The main drag is weak cash conversion: TTM operating cash flow and free cash flow are negative (~-$0.11M), raising durability and liquidity concerns despite reported profitability.

Income Statement

72Positive

Balance Sheet

78Positive

Cash Flow

41Neutral

Financial statement breakdown
Breakdown	TTM	Mar 2026	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.02M	2.69M	2.13M	1.41M	1.24M	1.41M
Gross Profit	2.02M	1.81M	1.36M	793.61K	619.52K	670.75K
EBITDA	718.32K	785.56K	352.39K	-91.29K	-434.60K	-487.63K
Net Income	524.11K	457.42K	-259.24K	-468.36K	-996.00K	-770.18K
Balance Sheet
Total Assets	1.93M	2.17M	1.80M	1.68M	1.96M	2.21M
Cash, Cash Equivalents and Short-Term Investments	317.39K	636.16K	157.17K	51.58K	178.69K	286.86K
Total Debt	95.55K	20.00K	1.72M	1.78M	1.68M	1.30M
Total Liabilities	375.82K	546.08K	2.41M	2.06M	1.88M	1.38M
Stockholders Equity	1.56M	1.62M	-607.76K	-375.62K	76.25K	824.07K
Cash Flow
Free Cash Flow	-107.43K	178.12K	142.44K	-159.63K	-388.11K	-509.31K
Operating Cash Flow	-107.43K	178.12K	142.44K	-159.63K	-350.99K	-354.74K
Investing Cash Flow	0	0	0	0	-37.12K	-154.57K
Financing Cash Flow	256.46K	300.87K	-36.85K	32.52K	279.95K	701.82K

QHSLab Technical Analysis

Technical Analysis SentimentNegative

Last Price0.30

Price Trends

50DMA0.35Negative

100DMA0.33Negative

200DMA0.48Negative

Market Momentum

MACD-0.02Positive

RSI41.87Neutral

STOCH1.92Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USAQ, the sentiment is Negative. The current price of 0.30 is below the 20-day moving average (MA) of 0.37, below the 50-day MA of 0.35, and below the 200-day MA of 0.48, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 41.87 is Neutral, neither overbought nor oversold. The STOCH value of 1.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for USAQ.

QHSLab Risk Analysis

QHSLab disclosed 43 risk factors in its most recent earnings report. QHSLab reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

QHSLab Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

USAQ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
USAQ	66Neutral	$4.51M	6.33	51.21%	―	24.61%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AEMD	49Neutral	$8.73M	-0.46	-123.09%	―	―	87.54%
NUWE	40Underperform	$3.07M	-0.00	-605.75%	―	8.36%	88.88%

* Healthcare Sector Average

Performance Comparison

USAQ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
USAQ	QHSLab, Inc.	0.30	0.14	84.05%
NUWE	Nuwellis, Inc.	5.68	-866.37	-99.35%
AEMD	Aethlon	5.44	-19.16	-77.89%
BBLG	Bone Biologics Corp	0.38	-1.66	-81.37%

QHSLab Corporate Events

Business Operations and StrategyFinancial Disclosures

QHSLab Reports Strong Q2 Growth in ISP Revenue

Positive

Aug 3, 2026

On August 3, 2026, QHSLab reported unaudited results for the second quarter and first half of 2026, highlighting strong growth in its Integrated Service Program revenue and a shift toward a recurring, software-enabled healthcare platform. Management...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 16, 2026

QHSLab AI Stock Analysis